Latest From Biotech Now

Biofuels Digest Measures Bioenergy Business Outlook

biofuel-plant-btn

Biofuels Digest and BIO launched the 2012 Q1 Bioenergy Business Outlook Survey. In the last survey, Biofuels Digest reported that 79 percent of bioenergy executives are more optimistic both about their organization’s prospects for growth and industry growth, than 12 months prior. Bioenergy, biofuel and biotech executives are invited to participate in the survey. Overall, the survey painted a picture of an industry that is expecting to grow at nearly triple the growth rate of Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Does Biotech History Repeat?

IPO-windows-btn

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history. When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Sen. Bob Menendez & William Waddill on the Therapeutic Discovery Project

sen-menendez

Senator Bob Menendez (D-NJ), at the March 6th Senate Banking, Housing and Urban Affairs hearing, emphasizes the effectiveness of the 2010 Therapeutic Discovery Project, the need to extend the program, and asks William Waddill, CFO/SVP of OncoMed Pharmaceuticals to share his company’s success story as a result of receiving an award. Read testimony from Waddill on the importance of capital formation.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

What Parallel Review Means for Manufacturers

Drug Manufacturing

By Stephen Rothenberg, J.D. and Matt Levy, J.D., Numerof & Associates, Inc. (NAI) Currently, the FDA and CMS consider new medical products in series; after FDA approval or clearance, CMS begins consideration of a National Coverage Determination (NCD), if requested by an interested stakeholder. Any party seeking drug approval (e.g., manufacturers, suppliers, providers, medical professional organizations, and Medicare beneficiaries) may initiate a request for an NCD. In addition, CMS may initiate a request for an Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Programming Updates to the 2012 BIO International Convention

sarah-thumb

With Convention less than four months away, things are quickly falling in to place with several programming updates to note! A total of 115 breakout sessions have been confirmed and scheduled, including 18 international case studies.  Session organizers are currently finalizing speakers.  All session descriptions and confirmed speakers are available on myBIO. Even after all of the session submissions work, we asked for more session ideas! We recently completed a call for “Late-Breaking” sessions in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,